Related Experiment Video

Updated: Jan 7, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Quantifying benefit of adding docetaxel to androgen receptor-axis therapy in metastatic hormone-sensitive prostate

Wei Chen1,2, Soichiro Yoshida3, Shugo Yajima4

  • 1Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

International Urology and Nephrology
|January 4, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Experiment Videos

Last Updated: Jan 7, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

The Value of Bayesian Statistics in Prostate Cancer Research: A Clinician-Oriented Review.

Clinical genitourinary cancer·2026

Comparison of Autonomic Nervous System Modulation Between Conventional and Novel Cryoballoon Systems.

Circulation reports·2026

Transition from drug lag to drug loss in pediatric oncology: a comprehensive evaluation of the Japan-U.S. approval gap.

Frontiers in pharmacology·2026

Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis.

International urology and nephrology·2026

Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis.

Critical reviews in oncology/hematology·2026

Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross-Trial Synthesis of Benefit Probabilities and Decision Thresholds.

Lower urinary tract symptoms·2026

KLF transcription factors in metabolic kidney disease: from podocyte protection to tubulointerstitial fibrosis.

International urology and nephrology·2026

Segmental ureterectomy versus radical nephroureterectomy for middle and distal ureteral tumors associated with hydronephrosis: a comparative analysis of oncological outcomes and postoperative renal function.

International urology and nephrology·2026

Relationship between remnant cholesterol and acute kidney injury in ICU patients: insights derived from MIMIC IV.

International urology and nephrology·2026

Effects of neuromuscular electrical stimulation (NMES) in patients undergoing haemodialysis: a systematic review and meta-analysis.

International urology and nephrology·2026

Sexual dysfunction in peritoneal dialysis: associated factors and exploratory machine-learning classification.

International urology and nephrology·2026

mpMRI-based clinic-radiomics-deep learning model integrating lesion and PPAT for predicting csPCa in PI-RADS category 3 lesions: a multicenter study.

International urology and nephrology·2026

Immune Cell Engager Therapy for Brain Cancer.

Neuro-oncology·2026

Gut microbiota-mediated dietary lignans metabolism drives accumulation of N,N-dimethylsphingosine and sensitizes triple-negative breast cancer to paclitaxel.

Food & function·2026

Ocular Microcystic Adnexal Carcinoma With High-Grade Features: A Case Report With Orbital Exenteration.

International journal of surgical pathology·2026

Effect of photobiomodulation therapy on regulating reparative processes of chronic wounds at the inflammation stage.

Biomedica : revista del Instituto Nacional de Salud·2026

Doxorubicin and 4-Hydroperoxycyclophosphamide Alter Mitochondrial Dynamics and miR-34 Expression in Spermatogonia and Spermatocytes In Vitro.

Basic & clinical pharmacology & toxicology·2026

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma.

Current opinion in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us